Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

By L. Johnson, R. Morgan, M. Dudley, L. Cassard, Jie Yang, M. Hughes, U. Kammula, R. Royal, R. Sherry, J. Wunderlich and 15 more. Blood, 2009

1,438 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/6c29389be17dd5c3b819e8591916bff2d65297ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. S. Rosenberg
2. C. June
3. Wendell A. Lim
4. N. Restifo
5. B. Levine
6. M. Dudley
7. G. Linette
8. B. Carreno

In Immunology

1. S. Rosenberg
2. N. Restifo
3. M. Dudley
4. C. June
5. Jie Yang
6. R. Sherry
7. U. Kammula
8. M. Hughes

In Oncology

1. S. Rosenberg
2. C. June
3. Wendell A. Lim
4. N. Restifo
5. M. Dudley
6. Jie Yang
7. B. Levine
8. R. Sherry

Citations in the corpus

• Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (2013, background): “Such “on-target” toxicity has been reported in recent studies; for example, T cells engineered with a TCR specific for the carcinoembryonic antigen induced severe inflammatory colitis (3), whereas T cells targeting melanoma antigens brought about destruction of normal melanocytes in the skin, ears, ”
• Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (2013, background): “Other instances of on-target off-tumor toxicity have been reported in patients with T cells engineered with a TCR specific for the carcinoembryonic antigen resulting in colitis,(26) and TCRs targeting melanoma antigens destroyed normal melanocytes in the skin, ears, and eyes.(27) The cardiac toxicit”
• Adoptive immunotherapy for cancer: harnessing the T cell response (2012, background): “Ve bu zararlı etkiler bazen kortikosteroit tedavisiyle müdahale gerektirebilir (21).”
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011, methodology): “Patient pheresis samples were stimulated using 50 ng/mL of soluble anti-CD3 antibody (OKT3; Ortho-Biotech, Bridgewater, NJ) in the presence of 300 iU of recombinant IL-2, transduced with a retrovirus encoding the modified 1G4- 95:LY anti– NY-ESO-1 TCR using retronectin, kindly provided by Takara Bio”
• A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014, methodology): “PBMCs obtained from patient phereses were stimulated using 50 ng/mL of soluble anti-CD3 antibody (OKT3; Ortho-Biotech) in the presence of 300 IU of recombinant IL2, transduced with a retrovirus encoding the modified 1G4-a95:LY anti-NY-ESO-1 TCR using retronectin, kindly provided by Takara Bio Inc, a”
• The Principles of Engineering Immune Cells to Treat Cancer (2017, result): “A higher-affinity TCR, tested in a second trial, showed very different results: most patients developed severe toxicity, including sloughing of skin, inflamed eyes, and loss of hearing that required treatment with steroids (Johnson et al., 2009).”
• Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. (2010, methodology): “PBLs were obtained from melanoma patients on protocol and stimulated in vitro and transduced with TCR-encoding retroviral vectors as previously described (12).”
• IL-2: The First Effective Immunotherapy for Human Cancer (2014, background): “The first example of the successful use of genetically engineered lymphocytes grown in IL-2 to mediate tumor rejection in humans was reported in 2006 using autologous lymphocytes genetically engineered with retroviruses encoding a high-affinity receptor against the MART-1 melanoma/ melanocyte Ag and”